Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing’s disease: results from an open-ended, open-label extension trial
Crossref DOI link: https://doi.org/10.1007/s11102-014-0618-1
Published Online: 2014-12-24
Published Print: 2015-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Schopohl, Jochen
Gu, Feng
Rubens, Robert
Van Gaal, Luc
Bertherat, Jérôme
Ligueros-Saylan, Monica
Trovato, Andrew
Hughes, Gareth
Salgado, Luiz R.
Boscaro, Marco
Pivonello, Rosario
License valid from 2014-12-24